Serum ACE
[Serum ACE]
EPTIS Ringversuch Nr. 142643 | Letze Änderung 2024-05-21 | URL: https://www.eptis.bam.de/pts142643 https://www.eptis.bam.de/pts142643
| Name des Anbieters | |||||||
| Name des Anbieters | Weqas Weqas | ||||||
| Ansässig in | United Kingdom | ||||||
| Sprache(n) | |||||||
| Anmerkungen | ACE (angiotensin I converting enzyme) is as a key component of the renin-angiotensin system, whose main function is to process angiotensin I to angiotensin II and degrade bradykinin. The renin-angiotensin system is responsible for the maintenance of normal blood pressure and electrolyte balance. ACE is expressed in endothelial and epithelial cells and is found in arterioles, muscular arteries and capillaries in the lungs, as well as the kidney. Three liquid human serum samples are distributed bimonthly, with a minimum of 18 samples distributed over the year covering a wide, clinically relevant range. A panel of 7 samples are produced from blood donations from healthy volunteers and patients to cover the normal and pathological clinical range. Four of the pools are distributed 3 times and 3 pools distributed twice. The programme assesses both laboratory and method performance, including bias, within and between batch imprecision and linearity. Key Features: - Liquid human serum samples require no pre-analytical preparation. - Endogenous samples commutable across all testing platforms. - Pathological range covered. - Scoring based on Milan Model 3 performance specification. - Each donation is distributed on a number of occasions over the year to assess both laboratory and method performance, including bias, within and between batch imprecision. For more information: https://www.weqas.com/services/eqa/serumace/ or contact@weqas.com | ||||||
| Klassifizierung | |||||||
| Produktgruppen |
Health care / medical devices
|
||||||
| Prüfgebiete |
Medical analysis
|
||||||
| Technische Einzelheiten | |||||||
|
|||||||
| Ringversuchsziele | |||||||
| Zielgruppe des Ringversuchs | The programme assesses both laboratory and method performance, including bias, within and between batch imprecision and linearity. | ||||||
| Relevante Rechtsvorschriften oder Normen | Accreditation by UKAS on the basis of ISO/IEC 17025, 17043 and 15195 | ||||||
| Weitere Ziele | validation of testing methods | ||||||
| Teilnehmerzahl | |||||||
| Anbieter unabhängig überprüft (akkreditiert, benannt, anerkannt) |
Akkreditiert durch UKAS auf der Grundlage von ISO/IEC 17043 |
||||||
| Die Durchführung des Ringversuchs ist in Auftrag gegeben durch | |||||||
| Kosten | |||||||
| Teilnahmegebühr | Fee dependent on number of participating sections and proximetry of testing methods. | ||||||
| Regelmässig durchgeführt | Ja (Frequency: Bimonthly. Samples: 3 x 0.5mL) | ||||||
| Der Ringversuch wird durchgeführt seit | 2010 | ||||||
| Kontaktdaten des Anbieters | |||||||
| Anbieter | Kontaktperson | ||||||
|
Weqas
Unit 6, Parc Ty Glas CF14 5DU Cardiff United Kingdom Telefon: 44 (0) 2920 314750 Fax: Web: http://www.weqas.com http://www.weqas.com |
Laura Lloyd-Lewis
Telefon: 44 (0) 29218 32884 Fax: E-Mail: laura.lloyd-lewis@wales.nhs.uk laura.lloyd-lewis@wales.nhs.uk |
||||||
Haben Sie einen Fehler entdeckt? Bitte wenden Sie sich an den zuständigen EPTIS Koordinator für United Kingdom,
Mr Savvas Xystouris.
Mr Savvas Xystouris.